Securities Registration Statement (s-1/a)
June 13 2017 - 2:46PM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on June 13, 2017
Registration
No. 333-218140
UNITED
STATES
securities
and exchange commission
Washington,
D.C. 20549
Pre-Effective
Amendment
No. 3
to
form
s-1
Registration
Statement Under The Securities Act of 1933
Interpace
Diagnostics Group, Inc.
(Exact
name of Registrant as specified in its charter)
Delaware
|
|
3841
|
|
22-2919486
|
(State
or other jurisdiction
of
incorporation or organization)
|
|
(Primary
Standard Industrial
Classification Code Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
Morris
Corporate Center 1, Building A
300
Interpace Parkway, Parsippany, NJ 07054
(844)
405-9655
(Address,
including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
Jack
Stover
President
and Chief Executive Officer
Interpace
Diagnostics Group, Inc.
Morris
Corporate Center 1, Building A
300
Interpace Parkway, Parsippany, NJ 07054
(844)
405-9655
(Name,
address, including zip code, and telephone
number, including area code, of agent for service)
COPIES
TO:
Merrill
M. Kraines, Esq.
Pepper
Hamilton LLP
The
New York Times Building
37
th
Floor 620 Eighth Avenue
New
York, NY 10018-1405
(212)
808-2711
|
|
Barry
I. Grossman, Esq.
Benjamin
S. Reichel, Esq.
Ellenoff
Grossman & Schole LLP
1345
Avenue of the Americas
New
York, NY 10105
(212)
370-1300
|
Approximate
date of commencement of proposed sale to the public:
As
soon as practicable after this Registration Statement becomes effective.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box. [X]
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933,
please check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering [ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering
[ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
|
|
[ ]
|
|
Accelerated
filer
|
|
[ ]
|
Non-accelerated
filer
|
|
[ ]
(Do not check if a smaller reporting company)
|
|
Smaller
reporting company
|
|
[X]
|
Emerging
Growth Company
|
|
[ ]
|
|
|
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided in Section 7(a)(2)(B) of the Securities Act. [ ]
CALCULATION OF REGISTRATION FEE
|
Title of Each Class of Securities to be Registered(1)
|
|
Proposed Maximum
Aggregate Offering
Price(2)(3)
|
|
|
Amount of
Registration Fee
|
|
Common stock, $0.01 par value per share
|
|
$
|
14,950,000
|
(4)
|
|
$
|
1,732.71
|
|
Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof
|
|
$
|
14,950,000
|
(4)
|
|
$
|
1,732.71
|
|
Common warrants to purchase shares of common stock
|
|
$
|
|
(5)(7)
|
|
$
|
|
|
Shares of common stock issuable upon exercise of the common warrants
|
|
$
|
17,940,000
|
(8)
|
|
$
|
2,079.25
|
|
Total
|
|
$
|
47,840,000
|
|
|
$
|
5,544.67
|
(6)
|
(1)
|
Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issuable to prevent dilution resulting from stock splits, stock dividends or similar transactions.
|
|
|
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act.
|
|
|
(3)
|
Includes the offering price of additional securities that the underwriters have the option to purchase.
|
|
|
(4)
|
The proposed maximum offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants offered and sold in the offering, and as such the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, will remain at $14,950,000.
|
|
|
(5)
|
The common warrants to be issued to investors hereunder are included in the price of the common stock and/or pre-funded warrants, as applicable, above.
|
|
|
(6)
|
Of which $3,811.96 was previously paid.
|
|
|
(7)
|
No fee pursuant to Rule 457(g) under the Securities Act.
|
|
|
(8)
|
We assumed the common warrants were exercisable at a per share exercise price equal to 120% of the public offering price. The proposed maximum aggregate public offering price of the warrants was calculated to be $17,940,000, which is equal to 120% of $14,950,000
|
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective
on such date as the Commission, acting pursuant to Section 8(a), may determine.
EXPLANATORY NOTE
This Amendment No. 3 to the Registration
Statement on Form S-1 is being filed solely to correct the amount of the applicable registration fee with respect to the potential
aggregate offering price of the pre-funded warrants. Accordingly, a preliminary prospectus has been omitted.
PART
II
Information
Not Required in Prospectus
ITEM
13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The
following table sets forth the fees and expenses, other than placement agent fees and expenses, payable in connection with the
registration of the common stock hereunder. All amounts are estimates except the SEC registration fee and the FINRA filing fee.
Item
|
|
Amount to
be paid
|
|
SEC registration fee
|
|
$
|
5,544.67
|
|
FINRA filing fee
|
|
$
|
5,680
|
|
Printing expenses
|
|
|
25,000
|
|
Legal fees and expenses
|
|
|
275,000
|
|
Accounting fees and expenses
|
|
|
50,000
|
|
Transfer Agent fees and expenses
|
|
|
5,000
|
|
Miscellaneous expenses
|
|
|
0
|
|
Total
|
|
|
366,224.67
|
|
ITEM
14. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Our
Certificate of Incorporation, as amended and as may be further amended and in effect from time to time, which we refer to as the
amended certificate of incorporation, provides that our directors shall not be personally liable to us or our stockholders for
monetary damages for any breach of fiduciary duty as a director, except for liability for breach of the director’s duty
of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing
violation of law, for payment of dividends or approval of stock purchases or redemptions that are prohibited by the General Corporation
Law of the State of Delaware, as amended, which we refer to as the DGCL, or for any transaction from which the director derived
an improper personal benefit. Under the DGCL, our directors have a fiduciary duty to us that is not eliminated by this provision
of the amended certificate of incorporation and, in appropriate circumstances, equitable remedies such as injunctive or other
forms of non-monetary relief will remain available. This provision also does not affect our directors’ responsibilities
under any other laws, such as federal securities laws or state or federal environmental laws.
Section
145 of the DGCL empowers a corporation to indemnify its directors and officers against expenses (including attorneys’ fees),
judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit
or proceeding brought by third parties by reason of the fact that they were or are directors or officers of the corporation, if
they acted in good faith, in a manner they reasonably believed to be in or not opposed to the best interests of the corporation
and, with respect to any criminal action or proceeding, had no reasonable cause to believe that their conduct was unlawful. The
DGCL provides further that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which
the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise.
The amended certificate of incorporation provides that, to the fullest extent permitted by Section 145 of the DGCL, we shall indemnify
any person who is or was a director or officer of us, or is or was serving at our request as a director, officer or trustee of
another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against the expenses, liabilities
or other matters referred to in or covered by Section 145 of the DGCL. Our amended and restated bylaws provide that we will indemnify
any person who was or is a party or threatened to be made a party to any proceeding by reason of the fact that such person is
or was a director or officer of us or is or was serving at our request as a director, officer or trustee of another corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise to the fullest extent permitted by the DGCL. In
addition,
we have entered into agreements with each of our directors and officers under which, among other things, we have agreed to indemnify
the director or officer against expenses incurred in any proceeding, including any action by us, in which the director or officer
was, is or is threatened to be made a party or a participant by reason of his or her status as a present or former director, officer,
employee or agent of us or, at our request, any other corporation, partnership, joint venture, trust, employee benefit plan or
other enterprise. At present, there is no pending litigation or proceeding involving any director or officer as to which indemnification
will be required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for
such indemnification.
Section
145 of the DGCL also empowers a corporation to purchase insurance for its officers and directors for such liabilities. We maintain
liability insurance for our officers and directors.
ITEM
15. RECENT SALES OF UNREGISTERED SECURITIES
The
following summarizes the securities that we sold within the past three years without registering the securities under the Securities
Act. All of these sales were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities
Act of 1933, as amended.
On
October 31, 2014, we issued an interest-free Note to RedPath Equityholder Representative, LLC (the “Equityholder Representative”),
on behalf of the equityholders of RedPath (the “Equityholders”), at the closing of the Agreement and Plan of Merger
(the “Agreement”), dated October 31, 2014, to acquire RedPath Integrated Pathology, Inc. (“RedPath”) for
$11.0 million to be paid in eight equal consecutive quarterly installments beginning October 1, 2016. We also entered into the
Contingent Consideration Agreement with the Equityholder Representative.We agreed to issue to the Equityholders 500,000 shares
of our common stock, par value $0.01, upon acceptance for publication of a specified article related to PathFinderTG ® for
the management of Barrett’s esophagus, and an additional 500,000 shares of the Company’s Common Stock upon the commercial
launch of PathFinderTG ® for the management of Barrett’s esophagus.
On
January 20, 2017, we entered into a placement agency agreement with Maxim Group LLC in connection with the registered direct public
offering of 855,000 shares of our common stock, par value $0.01 per share. In a concurrent private placement, we agreed to sell
through Maxim Group LLC as placement agent warrants to purchase 855,000 shares of common stock (the “Concurrent Warrants”)
with an exercise price of $4.69 per Concurrent Warrant. The combined purchase price for one common share and one Concurrent Warrant
was $4.69.
In
March 29, 2017 we agreed to issue 5-year warrants for an aggregate 100,000 shares of our common stock at an exercise price
of $4.69 to the former RedPath equity shareholders (our former secured creditors) in exchange for the termination of future royalty
and milestone payments related to sales of certain of our products arising out of our acquisition of Redpath Integrated Pathology
Inc. in October 2014.
On
April 18, 2017, we entered into an amendment and exchange agreement with an institutional investor, and agreed to exchange $3,547,775
of our senior secured note, dated March 23, 2017, for $3,547,775 of our senior secured convertible note, dated April 18, 2017.
The senior secured convertible note is identical in all material respects to our senior secured convertible note dated March 23,
2017 except for the initial conversion price and requiring stockholder approval to adjust the conversion price or the right to
substitute the variable price for the conversion price, which provisions have been waived by the investor. The initial conversion
price of the senior secured convertible note was $2.20.
Between
March 23, 2017 and April 18, 2017, we issued 3,795,429 shares of our common stock upon conversion of our senior secured convertible
notes. As a result, the outstanding amount of our senior secured convertible notes was reduced to zero.
|
|
Amount
of Senior
|
|
|
|
|
|
|
|
Date
of
|
|
Secured
Convertible Note
|
|
|
Shares
of
company
|
|
|
Conversion
price
|
|
Conversion
|
|
so
converted
|
|
|
stock
issued
|
|
|
per
share
|
|
March
23, 2017
|
|
$
|
122,000
|
|
|
|
50,000
|
|
|
$
|
2.44
|
|
March
28, 2017
|
|
|
25,000
|
|
|
|
10,248
|
|
|
|
2.44
|
|
March
29, 2017
|
|
|
1,275,000
|
|
|
|
522,648
|
|
|
|
2.44
|
|
March
30, 2017
|
|
|
2,799,663
|
|
|
|
1,147,638
|
|
|
|
2.44
|
|
April
3, 2017
|
|
|
200,000
|
|
|
|
81,992
|
|
|
|
2.44
|
|
April
18, 2017
|
|
|
900,000
|
|
|
|
369,126
|
|
|
|
2.44
|
|
April
18, 2017
|
|
|
3,547,775
|
|
|
|
1,613,777
|
|
|
|
2.20
|
|
Totals
|
|
$
|
8,869,438
|
|
|
|
3,795,429
|
|
|
|
|
|
ITEM
16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
See
the Exhibit Index included following the signature page of this registration statement.
ITEM
17. UNDERTAKINGS
Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Act, may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed
in the Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final adjudication of such issue.
The
undersigned registrant hereby undertakes:
|
(1)
|
To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
|
(i)
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective registration statement.
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;
|
(2)
|
That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
|
|
|
|
|
(3)
|
To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
|
|
|
|
|
(4)
|
That,
for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned
registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
|
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
(5)
|
For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the
registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.
|
|
|
|
|
(6)
|
For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this amendment to be signed on its
behalf by the undersigned, thereunto duly authorized in the City of Parsippany, State of New Jersey, on June 13,
2017.
|
|
INTERPACE
DIAGNOSTICS GROUP, INC.
|
|
|
|
|
By:
|
/s/
Jack E. Stover
|
|
|
Jack
E. Stover
|
|
|
President
and Chief Executive Officer
|
Pursuant
to the requirements of the Securities Act of 1933, this amendment has been signed by the following persons in the capacities and
as of the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Jack E. Stover
|
|
President,
Chief Executive Officer,
|
|
June
13, 2017
|
Jack
E. Stover
|
|
and
Director
|
|
|
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/
James E. Early
|
|
Chief
Financial Officer
|
|
June
13, 2017
|
James
E. Early
|
|
(Principal
Financial Officer and Principal
Accounting Officer)
|
|
|
|
|
|
|
|
/s/
Jack E. Stover *
|
|
Director
|
|
June
13, 2017
|
Joseph
Keegan, PhD
|
|
|
|
|
|
|
|
|
|
/s/
Jack E. Stover *
|
|
Director
|
|
June
13, 2017
|
Stephen
J.
Sullivan
|
|
|
|
|
*
Pursuant to power of attorney
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
|
|
|
1.1 *
|
|
Form
of Underwriting Agreement
|
|
|
|
2.1*
|
|
Asset
Purchase Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference
to the designated exhibit of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed
with the SEC on November 5, 2014
|
|
|
|
2.2*
|
|
Agreement
and Plan of Merger, dated October 31, 2014, by and among RedPath Integrated Pathology, Inc., the Company, Interpace Diagnostics,
LLC, RedPath Acquisition Sub, Inc. and RedPath Equityholder Representative, LLC, incorporated by reference to the designated
exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March
5, 2015
|
|
|
|
2.3*
|
|
Asset
Purchase Agreement, dated as of October 30, 2015, by and between Publicis Touchpoint Solutions, Inc. and PDI, Inc. is incorporated
by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 2, 2015
|
|
|
|
3.1*
|
|
Certificate
of Incorporation of PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.), incorporated by reference to the designated exhibit
of the Company’s Registration Statement on Form S-1 (File No. 333-46321), filed with the SEC on May 19, 1998
|
|
|
|
3.2*
|
|
Certificate
of Amendment of Certificate of Incorporation of PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.), incorporated by reference
to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2001, filed with
the SEC on March 13, 2002
|
|
|
|
3.3*
|
|
Certificate
of Amendment to the Certificate of Incorporation of PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.), incorporated by
reference to the designated exhibit of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012,
filed with the SEC on August 14, 2012
|
|
|
|
3.4*
|
|
Amended
and Restated By-Laws of PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.), incorporated by reference to the designated
exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March
6, 2014
|
|
|
|
3.5*
|
|
Certificate
of Amendment to the Certificate of Incorporation of PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.), incorporated by
reference to the designated exhibit of the Company’s Form 8-K filed with the SEC on December 23, 2015
|
|
|
|
3.6*
|
|
Certificate
of Amendment to the Certificate of Incorporation of PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.), incorporated by
reference to the designated exhibit of the Company’s Form 8-K filed with the SEC on December 23, 2015
|
|
|
|
3.7*
|
|
Certificate
of Amendment to the Certificate of Incorporation of Interpace Diagnostics Group, Inc., incorporated by reference to the designated
exhibit of the Company’s Current Report on Form 8-K filed with the SEC on December 28, 2016
|
|
|
|
3.8*
|
|
Form
of Warrant to Purchase Stock of Interpace Diagnostics Group, Inc., issued to purchasers of convertible promissory notes (incorporated
by reference to Exhibit 4.5 to the Company’s Form 10-K, filed with the SEC on March 9, 2016)
|
|
|
|
4.1*
|
|
Specimen
Certificate Representing the Common Stock, incorporated by reference to the designated exhibit of the Company’s Registration
Statement on Form S-1 (File No. 333-46321), filed with the SEC on May 19, 1998
|
4.2*
|
|
Form of Prepaid Common Stock Purchase Warrant, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on December 19, 2016
|
|
|
|
4.3
*
|
|
Form of Pre-Funded Warrant
|
|
|
|
4.4*
|
|
Form of Common Warrant
|
|
|
|
4.5*
|
|
Form of Underwriter Warrant
|
|
|
|
4.6*
|
|
Form of Warrant Agreement
|
|
|
|
5.1
*
|
|
Opinion of counsel with respect to the legality of the securities being registered
|
|
|
|
10.1**
|
|
2000 Omnibus Incentive Compensation Plan, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2014
|
|
|
|
10.2**
|
|
Executive Deferred Compensation Plan, incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 8, 2010
|
|
|
|
10.3**
|
|
Amended and Restated 2004 Stock Award and Incentive Plan, incorporated by reference to the designated exhibit of the Company’s definitive proxy statement filed with the SEC on April 28, 2004
|
|
|
|
10.4**
|
|
Form of Restricted Stock Unit Agreement for Employees, incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 8, 2009
|
|
|
|
10.5**
|
|
Form of Stock Appreciation Rights Agreement for Employees, incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 8, 2009
|
|
|
|
10.6**
|
|
Form of Restricted Stock Unit Agreement for Directors, incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 8, 2009
|
|
|
|
10.7**
|
|
Form of Restricted Share Agreement, incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 8, 2010
|
|
|
|
10.8**
|
|
Offer Letter between the Company and Graham G. Miao, dated October 14, 2014, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2014
|
|
|
|
10.9**
|
|
Employment Separation Agreement between the Company and Graham G. Miao, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2014
|
|
|
|
10.10**
|
|
Confidential Information, Non-Disclosure, Non-Competition, Non-Solicitation and Rights to Intellectual Property Agreement between the Company and Graham G. Miao, dated October 14, 2014, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2014
|
|
|
|
10.11**
|
|
Form of Restricted Stock Unit Inducement Agreement, by and between the Company and Graham G. Mio, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2014
|
|
|
|
10.12**
|
|
Stock Appreciation Rights Inducement Agreement by and between the Company and Graham G. Miao, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2014
|
|
|
|
10.13*
|
|
Morris Corporate Center Lease, incorporated by reference to the designated exhibit of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, filed with the SEC on November 5, 2009
|
10.14*
|
|
Non-negotiable
Subordinated Secured Promissory Note, dated October 31, 2014, by the Company and Interpace Diagnostics, LLC in favor of RedPath
Equityholder Representative, LLC, incorporated by reference to the designated exhibit of the Company’s Annual Report
on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015
|
|
|
|
10.15*
|
|
Amendment
No. 1 to Note, dated July 30, 2015, by and between Redpath Equityholder Representative, LLC, a Delaware limited liability
company, and the Company, incorporated by reference to the designated exhibit of the Company’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2015, filed with the SEC on November 12, 2015
|
|
|
|
10.16*
|
|
Limited
Waiver, Consent and Amendment No. 2 to Note, dated October 30, 2015, by and among RedPath Equityholder Representative, LLC,
PDI, Inc., and Interpace Diagnostics, LLC, incorporated by reference to the designated exhibit of the Company’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2015, filed with the SEC on November 12, 2015
|
|
|
|
10.17*
|
|
Contingent
Consideration Agreement, dated October 31, 2014, by and among the Company, Interpace Diagnostics, LLC and RedPath Equityholder
Representative, LLC, incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2014, filed with the SEC on March 5, 2015
|
|
|
|
10.18*
|
|
Settlement
Agreement, dated January 28, 2013, by and between RedPath Integrated Pathology, Inc. (now known as Interpace Diagnostics Corporation)
and the United States of America, incorporated by reference to the designated exhibit of the Company’s Annual Report
on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015
|
|
|
|
10.19*
|
|
License
Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference
to the designated exhibit of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed
with the SEC on November 5, 2014
|
|
|
|
10.20*
|
|
CPRIT
License Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference
to the designated exhibit of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed
with the SEC on November 5, 2014
|
|
|
|
10.21*
|
|
Supply
Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference
to the designated exhibit of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed
with the SEC on November 5, 2014
|
|
|
|
10.22*
|
|
Guaranty,
dated August 13, 2014 by the Company in favor of Asuragen, Inc., incorporated by reference to the designated exhibit of the
Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5,
2014
|
|
|
|
10.23*
|
|
Lease,
dated October 10, 2007, by and between Spring Way Center, LLC and RedPath Integrated Pathology, Inc. (now known as Interpace
Diagnostics, LLC), incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for
the year ended December 31, 2014, filed with the SEC on March 5, 2015
|
|
|
|
10.24*
|
|
Lease
Renewal, dated April 3, 2013, by and between Spring Way Center, LLC and RedPath Integrated Pathology, Inc. (now known as Interpace
Diagnostics, LLC), incorporated by reference to the designated exhibit of the Company’s Annual Report on Form 10-K for
the year ended December 31, 2014, filed with the SEC on March 5, 2015
|
10.25*
|
|
Lease,
dated June 28, 2015, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to the designated
exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March
5, 2015
|
|
|
|
10.26*
|
|
Amendment
No. 1 to Lease, dated September 18, 2007, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by
reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014,
filed with the SEC on March 5, 2015
|
|
|
|
10.27*
|
|
Amendment
No. 2 to Lease, dated August 29, 2008, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference
to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with
the SEC on March 5, 2015
|
|
|
|
10.28*
|
|
Amendment
No. 3 to Lease, dated April 8, 2009, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference
to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with
the SEC on March 5, 2015
|
|
|
|
10.29*
|
|
Amendment
No. 4 to Lease, dated September 16, 2010, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by
reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014,
filed with the SEC on March 5, 2015
|
|
|
|
10.30*
|
|
Amendment
No. 5 to Lease, dated September 15, 2011, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by
reference to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014,
filed with the SEC on March 5, 2015
|
|
|
|
10.31*
|
|
Amendment
No. 6 to Lease, dated March 5, 2014, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference
to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with
the SEC on March 5, 2015
|
|
|
|
10.32*
|
|
Amendment
No. 7 to Lease, dated August 29, 2014, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference
to the designated exhibit of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with
the SEC on March 5, 2015
|
|
|
|
10.33**
|
|
Amendment
Agreement, dated December 7, 2015, by and between PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.) and Nancy S. Lurker,
incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on
December 8, 2015
|
|
|
|
10.34**
|
|
Agreement
and General Release, dated January 6, 2016, by and between Gerald Melillo and PDI, Inc. (n.k.a. Interpace Diagnostics Group,
Inc.), incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the
SEC on January 1, 2016
|
|
|
|
10.35**
|
|
Agreement
and General Release, dated January 15, 2016, by and between Nancy S. Lurker and PDI, Inc. (n.k.a. Interpace Diagnostics Group,
Inc.), incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K, filed with the
SEC on January 22, 2016.
|
|
|
|
10.36**
|
|
Severance
Agreement and General Release, dated March 28, 2016, by and between Graham Miao and Interpace Diagnostics Group, Inc., incorporated
by reference the designated exhibit of the Company’s Current Report on Form 8-K, filed with the SEC on March 29, 2016.
|
|
|
|
10.37**
|
|
Employment
Separation Agreement between Interpace Diagnostics Group, Inc. and Nat Krishnamurti, effective as of June 22, 2016, incorporated
by reference to the designated exhibit of Amendment No. 2 to the Company’s Current Report on Form 8-K filed with the
SEC on June 22, 2016.
|
|
|
|
10.38**
|
|
Confidential
Information, Non-Disclosure, Non-Solicitation, Non-Compete and Rights to Intellectual Property Agreement between Interpace
Diagnostics Group, Inc. and Nat Krishnamurti, dated as of June 22, 2016, incorporated by reference to the designated exhibit
of Amendment No. 2 to the Company’s Current Report on Form 8-K filed with the SEC on June 22, 2016.
|
10.39**
|
|
Form of Indemnification Agreement by and between Interpace Diagnostics Group, Inc. and its directors and executive officers, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2016.
|
|
|
|
10.40*
|
|
Credit Agreement and Security Agreement, dated as of September 28, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and SCM Specialty Finance Opportunities Fund, L.P., incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2016.
|
|
|
|
10.41*
|
|
Intercreditor Agreement, dated as of September 28, 2016, by and between SCM Specialty Finance Opportunities Fund, L.P. and RedPath Equityholder Representative, LLC and acknowledged and agreed to by Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and Interpace Diagnostics Corporation, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2016.
|
|
|
|
10.42*
|
|
Third Amendment to Non-Negotiable Subordinated Secured Promissory Note, dated as of September 30, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and RedPath Equityholder Representative, LLC, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2016.
|
|
|
|
10.43*
|
|
Management Engagement Letter, effective as of October 11, 2016, by and between Early Financial Consulting, LLC and Interpace Diagnostics Group, Inc., incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 14, 2016.
|
|
|
|
10.44**
|
|
Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and Jack E. Stover, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2016.
|
|
|
|
10.45**
|
|
Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and James Early, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2016.
|
|
|
|
10.46**
|
|
Form of Incentive Stock Option Agreement, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 20, 2016.
|
|
|
|
10.47*
|
|
Fourth Amendment to Non-Negotiable Subordinated Secured Promissory Note, dated as of October 31, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and RedPath Equityholder Representative, LLC, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on November 3, 2016.
|
|
|
|
10.48**
|
|
Employment Agreement, dated as of October 28, 2016, by and between Interpace Diagnostics Group, Inc. and Jack E. Stover, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on November 3, 2016.
|
|
|
|
10.49*
|
|
Fifth Amendment to Non-Negotiable Subordinated Secured Promissory Note, dated as of November 16, 2016, by and among Interpace Diagnostics Group, Inc., Interpace Diagnostics, LLC and RedPath Equityholder Representative, LLC, incorporated by reference to the designated exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 17, 2016.
|
|
|
|
10.50*
|
|
Placement Agency Agreement by and between Interpace Diagnostics Group, Inc. and Maxim Group, LLC, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on December 19, 2016.
|
|
|
|
10.51*
|
|
Form of Securities Purchase Agreement by and between Interpace Diagnostics Group, Inc. and certain purchasers named therein, incorporated by reference to the designated exhibit of the Company’s Current Report on Form 8-K filed with the SEC on December 19, 2016.
|
|
|
|
10.52
*
|
|
First Amendment of Lease, dated May 24, 2017, by and among Brookwood MC Investors, LLC, Brookwood MC II, LLC and Interpace Diagnostics Group, Inc.
|
|
|
|
10.53
*
|
|
Lease Agreement, dated March 31, 2017, by and between Saddle Lane Realty, LLC and Interpace Diagnostics Group, Inc.
|
|
|
|
21.1*
|
|
Subsidiaries of the Registrant, incorporated by reference to the designated exhibit to the Company’s Current Report on Form 8-K filed with the SEC on February 3, 2017.
|
|
|
|
23.1*
|
|
Consent of BDO USA LLP, Independent Registered Public Accounting Firm.
|
|
|
|
23.2*
|
|
Consent of Pepper Hamilton LLP (included in Exhibit 5.1).
|
|
|
|
24.1*
|
|
Power of Attorney (included as part of the signature pages hereto).
|
*
|
Previously
filed.
|
**
|
Indicates
a management contract or compensatory plan or arrangement.
|
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024